Covalon Technologies Ltd. (OTCMKTS:CVALF – Get Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 100 shares, a drop of 92.3% from the December 15th total of 1,300 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.0 days.
Covalon Technologies Stock Up 2.0 %
Covalon Technologies stock traded up $0.05 during midday trading on Wednesday, hitting $2.30. 23,400 shares of the stock were exchanged, compared to its average volume of 37,767. Covalon Technologies has a 52 week low of $0.74 and a 52 week high of $3.08. The stock has a market capitalization of $63.02 million, a PE ratio of -76.64 and a beta of -0.27. The company has a fifty day simple moving average of $2.49 and a two-hundred day simple moving average of $2.21.
Covalon Technologies (OTCMKTS:CVALF – Get Free Report) last announced its quarterly earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a negative net margin of 2.94% and a negative return on equity of 4.40%.
Covalon Technologies Company Profile
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.
Further Reading
- Five stocks we like better than Covalon Technologies
- Using the MarketBeat Dividend Tax Calculator
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- The 3 Best Fintech Stocks to Buy Now
- How Do Stock Buybacks Affect Shareholders?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Covalon Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covalon Technologies and related companies with MarketBeat.com's FREE daily email newsletter.